Other novel therapies for both early-onset AD (EOAD) and late-onset AD (LOAD) have focused on APP, PSEN1, and PSEN2, identified through rare mutations in familial EOAD cases, that cause amyloid-β deposition. The gene discussed is PSEN2; the disease is Alzheimer disease.